X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.reuters.com/legal/us-judge-overturns-eli-lillys-1765-million-loss-teva-patent-case-2023-09-26/
https://www.fiercepharma.com/pharma/teva-looks-humira-biosimilar-leans-ajovy-and-austedo-spark-faltering-growth
https://www.fiercepharma.com/pharma/after-abbvie-phrmas-black-sheep-teva-walks-away-influential-trade-group
https://www.otsuka.co.jp/en/company/newsreleases/2022/20221116_1.html
https://www.biospace.com/article/releases/teva-announces-promising-interim-results-from-its-study-pearl-about-the-impact-of-ajovy-fremanezumab-/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761089
https://www.fiercepharma.com/pharma/teva-trailing-cgrp-rivals-migraine-can-t-find-a-win-ajovy-analysis-versus-biohaven-and
https://www.biospace.com/article/releases/first-long-term-data-on-the-use-of-ajovy-fremanezumab-vfrm-injection-in-patients-with-migraine-published-in-neurology-/
https://www.canadianmanufacturing.com/manufacturing/teva-canada-announces-product-availability-of-ajovy-259254/
https://www.fiercepharma.com/pharma/teva-s-ajovy-launch-gains-steam-after-autoinjector-approval
https://www.tevapharm.com/news-and-media/latest-news/teva-announces-new-drug-application-filing-in-japan-for-ajovy-fremanezumab-injection/#:~:text=(NYSE%20and%20TASE%3A%20TEVA),the%20preventive%20treatment%20of%20migraine.
http://www.pharmatimes.com/news/uk_launch_for_ajovy_injector_pen_1345184
http://www.pharmatimes.com/news/nice_publishes_final_guidance_backing_tevas_ajovy_for_migraine_1341487
https://www.afp.com/en/news/1312/teva-presented-new-data-european-academy-neurology-congress-evaluating-ajovyr-fremanezumab-experience-populations-difficult-treat-migraine-202005240050151
https://www.fiercepharma.com/pharma/teva-walks-away-from-price-fixing-settlement-talks-amid-covid-19-chaos-report
https://www.businesswire.com/news/home/20200427005083/en/Teva-Announces-U.S.-Launch-Autoinjector-AJOVY%C2%AE-fremanezumab-vfrm
https://www.reuters.com/article/us-teva-lilly-patent/u-s-court-rules-for-teva-in-migraine-patent-dispute-with-eli-lilly-idUSKBN21I2WV?feedType=RSS&feedName=healthNews
https://www.fiercepharma.com/pharma/teva-s-ajovy-scores-backing-from-england-s-cost-watchdogs-thanks-to-discountv
http://www.pmlive.com/pharma_news/tevas_weak_pipeline_hit_by_tourettes_drug_trial_failure_1326565
https://www.fiercepharma.com/pharma/teva-s-global-restructuring-over-now-it-s-looking-to-ajovy-austedo-for-next-phase
https://finance.yahoo.com/news/teva-announces-positive-top-line-083000214.html
https://www.fiercepharma.com/pharma/teva-s-ajovy-finally-gets-autoinjector-nod-can-it-close-gap-amgen-lilly-meds
https://www.prnewswire.com/news-releases/nccn-oncology-research-program-to-oversee-trials-of-the-fgfr-inhibitor-futibatinib-in-tumors-with-aberrant-fgfr-expression-in-collaboration-with-taiho-oncology-300992953.html
https://www.fiercepharma.com/pharma/cgrp-market-race-heats-up-amgen-s-aimovig-slips-under-50-lilly-s-emgality-rise
https://www.biospace.com/article/teva-s-cgrp-inhibitor-reduces-monthly-migraine-days-in-late-stage-trial/
https://www.fiercepharma.com/marketing/biohaven-touts-oral-cgrp-data-moves-closer-to-regulatory-finish-line-and-maybe-m-a
https://www.fiercepharma.com/marketing/eli-lilly-turns-to-patients-to-market-new-emgality-indication-cluster-headaches
https://www.fiercepharma.com/pharma/lilly-scores-cluster-headache-nod-for-emgality-how-will-it-affect-cgrp-race
https://www.reuters.com/article/us-teva-pharm-ind-cluster-headache/teva-stops-testing-its-migraine-drug-as-cluster-headache-treatment-idUSKCN1RZ1EH?feedType=RSS&feedName=healthNews
https://www.fiercepharma.com/pharma/teva-ditches-trial-ajovy-cluster-headache-clearing-a-path-for-lilly-to-forge-a-new-market
http://www.pmlive.com/pharma_news/tevas_migraine_injection_approved_in_europe_1283616
Market Place
Share 
